# US 2026/0158062 A1 · Cryoprecipitate compositions and methods of preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0158062 A1
- Document ID: US20260158062A1
- Status: Published application
- Kind: A1
- Application number: 19/356,703
- Filed: 2025-10-13
- Published: 2026-06-11
- Earliest claimed: 2015-10-23
- Assignees: Cerus Corporation
- Applicants: Cerus Corporation
- Inventors: Laurence CORASH; Elan WEINER; Melody HOLTAN; Richard BENJAMIN
- Web page: https://patentgrep.com/patent/US20260158062A1

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61J 1/18: Arrangements for indicating condition of container contents, e.g. sterile condition
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/363: {Fibrinogen}
- A61K 38/37: Factors VIII
- A61K 41/17: by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
- A61L 2/10: Ultraviolet [UV] radiation
- A61M 1/0272: {Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging}
- A61M 1/0281: {Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61L 2/07: Steam
- A61L 2/081: Gamma radiation
- A61L 2/087: Particle radiation, e.g. electron-beam, alpha or beta radiation
- A61L 2103/05: Living organisms or biological materials
- A61L 2103/09: Blood or products thereof
- A61L 2103/23: {Containers other than laboratory or medical, e.g. bottles or mail}
- A61L 2202/181: Flexible packaging means, e.g. permeable membranes, paper
- A61M 1/3683: {using photoactive agents}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Provided herein are compositions and kits including a pathogen-inactivated cryoprecipitate suitable for infusion into a subject at least 1 day after thawing. The methods are useful in the efficient preparation of cryoprecipitates with desirable characteristics, including pathogen-inactivated cryoprecipitates that are suitable for infusion into a subject at least 1 day after thawing.

## Claims

### Claim at position 1

1-55. (canceled)

### Claim 56

A processing set for preparing a pathogen-inactivated cryoprecipitate, comprising
a) a first container within which one or more units of a plasma can be photochemically inactivated in the presence of a psoralen under sterile conditions;
b) a compound absorption device (CAD) coupled to the first container such that the one or more units of plasma can be transferred from the first container to the CAD under sterile conditions;
c) one or more second containers, each of which is coupled to the CAD such that the one or more units of plasma can be transferred from the CAD to the one or more second containers under sterile conditions to provide pathogen-inactivated plasma suitable for infusion into a subject; and
d) a third container, which is configured to be coupled to the one or more second containers such that the pathogen-inactivated plasma can be transferred from the one or more second containers to the third container under sterile conditions,
wherein the third container is suitable for freezing the pathogen-inactivated plasma followed by thawing of the pathogen-inactivated plasma under conditions that provide for the formation of a cryoprecipitate and a cryosupernatant.

### Claim 57 (depends on 56)

The processing set of claim 56, wherein the third container is suitable for freezing the pathogen-inactivated plasma, followed by thawing of the pathogen-inactivated plasma under conditions that provide for the formation of the cryoprecipitate and a cryosupernatant, followed by removal of all or a portion of the cryosupernatant from the third container.

### Claim 58 (depends on 56)

The processing set of claim 56, further comprising an additional container suitable for mixing the one or more units of plasma with a pathogen inactivation compound, wherein the additional container is coupled to the first container such that the one or more units of plasma in admixture with the pathogen-inactivating compound can be transferred from the additional container to the first container under sterile conditions.

### Claim 59 (depends on 57)

The processing set of claim 57, wherein the third container is configured for removal of all or a portion of the cryosupernatant from the third container into the one or more second containers.

### Claim 60 (depends on 57)

The processing set of claim 57, wherein, after removal of the portion of the cryosupernatant, the cryoprecipitate comprises a volume of between about 30 mL and about 150 mL of plasma.

### Claim 61 (depends on 56)

The processing set of claim 56, comprising three second containers.

### Claim 62 (depends on 61)

The processing set of claim 61, comprising a three-way lead of tubing, wherein the three-way lead of tubing is connected via the tubing to each of the three second containers, and wherein the third container further comprises tubing that is configured to be coupled via sterile connection to tubing connected to the three-way lead of tubing.

### Claim 63 (depends on 56)

The processing set of claim 56, wherein the processing set is configured for preparing the cryoprecipitate from at least about 550 mL and less than about 650 mL of pathogen-inactivated plasma.

### Claim 64 (depends on 56)

The processing set of claim 56, wherein a container containing a first cryoprecipitate preparation is configured to be connected to a container containing a second cryoprecipitate preparation for combining the first and second cryoprecipitate preparations.

### Claim 65 (depends on 56)

The processing set of claim 56, wherein the plasma is obtained from 2-6 donors.

### Claim 66 (depends on 56)

The processing set of claim 56, wherein the plasma is apheresis-collected plasma.

### Claim 67 (depends on 56)

The processing set of claim 56, wherein the plasma is whole blood-derived plasma.

### Claim 68 (depends on 67)

The processing set of claim 67, wherein the plasma is whole blood-derived plasma frozen within 24 hours of donation.

### Claim 69 (depends on 56)

The processing set of claim 56, further comprising a label indicating that the pathogen-inactivated cryoprecipitate is suitable for use for at least about 5 days after thawing.

### Claim 70 (depends on 56)

The processing set of claim 56, further comprising a label indicating that the pathogen-inactivated cryoprecipitate is suitable for use up to about 7 days after thawing.

### Claim 71 (depends on 56)

The processing set of claim 56, wherein the psoralen is amotosalen.
